Drug Profile

Tranexamic acid injection - Rafa Laboratories

Alternative Names: TXA injection - Rafa Laboratories

Latest Information Update: 19 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Rafa Laboratories
Class Amines; Anti-infectives; Anti-inflammatories; Antifibrinolytics; Antihaemorrhagics; Cardiovascular therapies; Cyclohexanecarboxylic acids; Skin disorder therapies; Small molecules
Mechanism of Action Antifibrinolytic agents; Plasminogen activator inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

18 Nov 2025 Rafa Laboratories receives contract from the Biomedical Advanced Research and Development Authority (BARDA) for novel intramuscular (IM) formulation of tranexamic acid development in haemorrhage
18 Nov 2025 Early research in Haemorrhage in Israel (IM), prior to November 2025

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com